Introduction Patients with relapsed or refractory multiple myeloma (RRMM) represent an
unmet clinical need. Belantamab mafodotin (belamaf; GSK2857916) is a first-in-class …

Belantamab mafodotin (belamaf) demonstrated deep and durable responses in patients with
heavily pretreated relapsed or refractory multiple myeloma (RRMM) in DREAMM-2 …

Immune-related adverse events (irAEs) is a term used to describe the various toxicities
associated with immune checkpoint inhibitor (ICI) use. As this class of cancer …

Immune checkpoint inhibitors (ICIs) have emerged as standard therapies for an increasing
number of advanced cancers. Nonspecific immune activation may lead to immune-related …

Foxp3+ regulatory T cells (Foxp3+ Treg) play a role in regulating various types of tumors, but
uncertainty still exists regarding the exact mechanism underlying Foxp3+ Treg activation in …

Introduction Audiovestibular toxicity secondary to immunotherapy has only rarely been
reported in the literature. Herein, we examine our experience diagnosing and managing …

Ocular immune-related adverse events are a relatively rare complication of immune
checkpoint inhibitors. Common ocular toxicities range from dry eyes to inflammatory uveitis …

Cancer therapy relies on new antitumoral drugs called immune checkpoint inhibitors (ICI),
which produce long-lasting anti-tumor responses and lengthen survival, but cause …

La terapia contra el cáncer cuenta con los nuevos inhibidores de puntos de fijación (ICI),
que producen respuestas antitumorales duraderas y alargan la supervivencia pero …

Bei zunehmend längeren Überlebensraten von Patienten mit Lungenkarzinom und einer
stetig wachsenden Bedeutung der ambulanten Behandlung rückt die Lebensqualität von …